Published in Osteoporos Int on October 30, 2007
Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res (2014) 1.52
Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int (2009) 1.47
An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int (2009) 1.31
Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int (2010) 1.18
Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporos Int (2012) 0.92
Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. Eur J Endocrinol (2011) 0.91
Challenges in implementing and maintaining osteoporosis therapy. Int J Womens Health (2014) 0.86
Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results from the European Forsteo Observational Study. J Osteoporos (2011) 0.86
Validation of the osteoporosis quality of life questionnaire QUALEFFO-41 for the Serbian population. Health Qual Life Outcomes (2012) 0.86
Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study. BMC Musculoskelet Disord (2013) 0.86
Bone health and deterioration in quality of life among participants from the Hertfordshire cohort study. Osteoporos Int (2009) 0.85
Predicting EQ-5D-US and SF-6D societal health state values from the Osteoporosis Assessment Questionnaire. Osteoporos Int (2011) 0.80
Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass. Osteoporos Int (2011) 0.80
Validation of the simplified Chinese version of the quality of life questionnaire of the European foundation for osteoporosis (QUALEFFO-31). Eur Spine J (2015) 0.75
Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial. Osteoporos Int (2017) 0.75
EuroQol--a new facility for the measurement of health-related quality of life. Health Policy (1990) 59.70
Modeling valuations for EuroQol health states. Med Care (1997) 21.66
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Epidemiology and outcomes of osteoporotic fractures. Lancet (2002) 13.09
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Risk of new vertebral fracture in the year following a fracture. JAMA (2001) 6.17
Osteoporosis. Lancet (2006) 5.40
A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 4.92
Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab (2000) 3.68
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med (2000) 3.16
Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91
Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res (2000) 2.55
Validity of self-report of fractures: results from a prospective study in men and women across Europe. EPOS Study Group. European Prospective Osteoporosis Study Group. Osteoporos Int (2000) 2.52
Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone (2004) 2.48
The accuracy of self-report of fractures in elderly women: evidence from a prospective study. Am J Epidemiol (1992) 2.33
Quality of life measures in health care. II: Design, analysis, and interpretation. BMJ (1992) 2.28
Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int (1999) 2.20
Quality of life in patients with osteoporosis. Osteoporos Int (2004) 2.14
A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med (2005) 2.07
Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int (2005) 2.05
The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum (2001) 2.00
Early discontinuation of treatment for osteoporosis. Am J Med (2003) 2.00
Health-related quality of life and radiographic vertebral fracture. Osteoporos Int (2003) 1.70
Tolerability and compliance with risedronate in clinical practice. Osteoporos Int (2003) 1.51
The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskelet Disord (2002) 1.47
Quality of life as outcome in the treatment of osteoporosis: the development of a questionnaire for quality of life by the European Foundation for Osteoporosis. Osteoporos Int (1997) 1.43
[Teriparatide: an anabolic drug for the treatment of patients with osteoporosis]. Ned Tijdschr Geneeskd (2006) 1.39
Validity of self-reports of fractures in perimenopausal women. Am J Epidemiol (1999) 1.38
Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures. Osteoporos Int (2004) 1.31
The impact of osteoporosis on quality-of-life: the OFELY cohort. Bone (2002) 1.26
A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporos Int (1999) 1.18
Comparison of generic and disease-specific questionnaires for the assessment of quality of life in patients with peripheral arterial disease. J Vasc Surg (2005) 1.15
Back pain, disability, and radiographic vertebral fracture in European women: a prospective study. Osteoporos Int (2004) 1.10
Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. Clin Ther (2004) 1.08
A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int (2002) 1.06
Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med (2002) 1.05
Impact of vertebral deformities, osteoarthritis, and other chronic diseases on quality of life: a population-based study. Osteoporos Int (2004) 1.03
Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis. Nephrol Dial Transplant (2004) 1.01
A new look at osteoporosis outcomes: the influence of treatment, compliance, persistence, and adherence. Mayo Clin Proc (2006) 1.00
Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev (2002) 0.93
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis (2003) 7.95
L-NG-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br J Pharmacol (1990) 7.27
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Simultaneous binding of PtdIns(4,5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes. Science (2001) 5.45
Movement of internalized ligand-receptor complexes along a continuous endosomal reticulum. Nature (1990) 5.41
A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess (2007) 5.29
EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2004) 4.94
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 4.83
General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre, randomised controlled trial. Lancet (2008) 4.18
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol (2002) 4.11
Case-control study of sudden infant death syndrome in Scotland, 1992-5. BMJ (1997) 4.03
Does cryptic gluten sensitivity play a part in neurological illness? Lancet (1996) 3.92
GTPase activity of dynamin and resulting conformation change are essential for endocytosis. Nature (2001) 3.90
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
Positional cloning of the gene associated with X-linked juvenile retinoschisis. Nat Genet (1997) 3.29
In migrating fibroblasts, recycling receptors are concentrated in narrow tubules in the pericentriolar area, and then routed to the plasma membrane of the leading lamella. J Cell Biol (1994) 3.19
Alendronate for the treatment of osteoporosis in men. N Engl J Med (2000) 3.11
Musculoskeletal pain in Europe: its impact and a comparison of population and medical perceptions of treatment in eight European countries. Ann Rheum Dis (2004) 2.95
In polarized MDCK cells basolateral vesicles arise from clathrin-gamma-adaptin-coated domains on endosomal tubules. J Cell Biol (1998) 2.95
Randomised controlled trial of exercise for low back pain: clinical outcomes, costs, and preferences. BMJ (1999) 2.94
Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int (1997) 2.80
Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int (2006) 2.79
Long-term observations of vertebral osteoporotic fractures treated by percutaneous vertebroplasty. Rheumatology (Oxford) (2000) 2.76
The effect of immunosympathectomy and of 6-hydroxydopamine on the responses of the rat anococcygeus to nerve stimulation and to some drugs. Br J Pharmacol (1973) 2.57
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
The state of basic surgical training in the UK: ophthalmology as a case example. J R Soc Med (2004) 2.51
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res (2003) 2.50
A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol (2000) 2.47
Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA (1997) 2.46
Effect of vascular occlusion on radiofrequency ablation of the liver: results in a porcine model. AJR Am J Roentgenol (2001) 2.34
How should we pay doctors? A systematic review of salary payments and their effect on doctor behaviour. QJM (1999) 2.26
The time course of a hypercalcaemic crisis in acute primary hyperparathyroidism. Lancet (1984) 2.21
Octreotide therapy for tumor-induced osteomalacia. N Engl J Med (2001) 2.19
EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT. Ann Rheum Dis (2008) 2.15
L-NG-nitro arginine inhibits non-adrenergic, non-cholinergic relaxations of guinea-pig isolated tracheal smooth muscle. Br J Pharmacol (1990) 2.12
Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.07
Transport into and out of the Golgi complex studied by transfecting cells with cDNAs encoding horseradish peroxidase. J Cell Biol (1994) 2.06
Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) (2007) 2.01
Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation. Kidney Int (2000) 1.99
The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum Mol Genet (2005) 1.94
Collaborative care for depression in UK primary care: a randomized controlled trial. Psychol Med (2007) 1.90
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia. Lancet (1998) 1.83
Quantitative heel ultrasound in a population-based study in Italy and its relationship with fracture history: the ESOPO study. Osteoporos Int (2005) 1.80
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res (2000) 1.80
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care (2001) 1.74
Reduction in sudden infant death syndrome in Scotland. Lancet (1992) 1.72
Detection of cases of inflammatory rheumatic disorders: performance of a telephone questionnaire designed for use by patient interviewers. Ann Rheum Dis (2003) 1.69
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int (2003) 1.65
Responses of the isolated anococcygeus muscle of the mouse to drugs and to field stimulation. J Auton Pharmacol (1981) 1.64
EVerT: cryotherapy versus salicylic acid for the treatment of verrucae--a randomised controlled trial. Health Technol Assess (2011) 1.62
L-NG-nitro-arginine and its methyl ester are potent inhibitors of non-adrenergic, non-cholinergic transmission in the rat anococcygeus. Br J Pharmacol (1990) 1.61
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) (2000) 1.59
UK Back pain Exercise And Manipulation (UK BEAM) trial--national randomised trial of physical treatments for back pain in primary care: objectives, design and interventions [ISRCTN32683578]. BMC Health Serv Res (2003) 1.57
Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study. Rheumatology (Oxford) (2006) 1.55
Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey. Osteoporos Int (2006) 1.54
The effects of drugs on the sensitivity of the rat anococcygeus muscle to agonists. Br J Pharmacol (1973) 1.53
Effects of the cyclin-dependent kinase inhibitor R-roscovitine on eosinophil survival and clearance. Clin Exp Allergy (2011) 1.53
Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J Virol Methods (2000) 1.50
Relative analgesia. An evaluation of the efficacy and safety. Br Dent J (1979) 1.48
Health targets in the NHS: lessons learned from experience with breast feeding targets in Scotland. BMJ (1997) 1.48
Modern laboratory diagnosis of tuberculosis. Lancet Infect Dis (2003) 1.48
Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann Rheum Dis (2009) 1.47
Three-dimensional electrical impedance tomography of human brain activity. Neuroimage (2001) 1.45
EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 1: prevalence of inflammation in osteoarthritis. Ann Rheum Dis (2005) 1.44
Bone loss in response to long-term glucocorticoid therapy. Bone Miner (1990) 1.44
Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab (1999) 1.43
Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.41
Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care Res (Hoboken) (2012) 1.40
Observation of B(0)(s)-->Psi(2S)Phi and measurement of the ratio of branching fractions Beta(B(0)(s)-->Psi(2S)Phi)/Beta(B(0)(s)-->J/PsiPhi). Phys Rev Lett (2006) 1.40
The Vein Graft Surveillance Trial: rationale, design and methods. VGST participants. Eur J Vasc Endovasc Surg (1999) 1.40
Complete recovery from hemorrhagic shock and encephalopathy. J Pediatr (1992) 1.40
Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano) (2001) 1.40
Alterations in bone mineral density and bone turnover markers in newly diagnosed adults with lymphoma receiving chemotherapy: a 1-year prospective pilot study. Ann Oncol (2014) 1.39
Measurement of dijet azimuthal decorrelations in pp collisions at sqrt(s)=7 TeV. Phys Rev Lett (2011) 1.39
Two distinct membrane currents activated by cyclopiazonic acid-induced calcium store depletion in single smooth muscle cells of the mouse anococcygeus. Br J Pharmacol (1996) 1.39
[Genetics of osteoporosis]. Dtsch Med Wochenschr (2003) 1.39
Reflections on the recommendations of the EWMA Patient Outcome Group document. J Wound Care (2010) 1.39
Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int (2009) 1.39
Peri-operative management of ophthalmic patients taking antithrombotic therapy. Int J Clin Pract (2011) 1.37
Don't wait for a sensory level--listen to the symptoms: a prospective audit of the delays in diagnosis of malignant cord compression. Clin Oncol (R Coll Radiol) (2002) 1.37
Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int (2003) 1.36
Complex effects of Gillichthys urotensin II on rat aortic strips. Br J Pharmacol (1987) 1.35
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
Selenium, the thyroid, and the endocrine system. Endocr Rev (2005) 1.33
Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Ann Rheum Dis (2005) 1.32
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
Effects of limb-length discrepancy on gait economy and lower-extremity muscle activity in older adults. J Bone Joint Surg Am (2001) 1.30
Randomisation methods in controlled trials. BMJ (1998) 1.30
Creatinuria in Certain Diseased Conditions. Can Med Assoc J (1922) 1.29
Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I. J Biol Chem (1996) 1.29
Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett (2013) 1.27
Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis (2005) 1.27
Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int (2012) 1.25
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res (2002) 1.22